A retrospective multicohort study has found that for patients with advanced solid tumours, including NPC, radiomics could also be used to assess CD8 cell tumour infiltration and elicit tumour immune phenotypes that can predict tumour response to anti-PD-1 and anti-PD-L1 therapy and overall survival [51]. Here, CD8A is linked to neoplasm.